Sen. Glenn retirement opens speculation on Senate bid by Health Subcmte. ranking Dem. Brown (D-Ohio).
Executive Summary
SEN. GLENN RETIREMENT OPENS SPACE FOR SENATE BID BY REP. BROWN, the new ranking Democrat on the House Commerce/Health & Environment Subcommittee. Brown has been suggested as one Ohio Democrat who could consider seeking the nomination to succeed Glenn in 1998. If he undertakes a Senate bid, Brown could be constricted in his ability to invest time and energy in broad, FDA-related issues. Brown's office says that he has no plans to run for the Senate. Reps. Kaptur and Traficant are also considered possible contenders for the Democratic Senate nomination in Ohio.
|
SEN. GLENN RETIREMENT OPENS SPACE FOR SENATE BID BY REP. BROWN, the new ranking Democrat on the House Commerce/Health & Environment Subcommittee. Brown has been suggested as one Ohio Democrat who could consider seeking the nomination to succeed Glenn in 1998. If he undertakes a Senate bid, Brown could be constricted in his ability to invest time and energy in broad, FDA-related issues. Brown's office says that he has no plans to run for the Senate. Reps. Kaptur and Traficant are also considered possible contenders for the Democratic Senate nomination in Ohio. As chairman of the Senate Government Relations Committee in 1991, Glenn convened hearings on the Edwards Commission report on FDA. More recently, his interest in the agency has been limited to constituent issues. In 1992, Glenn was the original sponsor of a failed legislative bid to provide an Olestra patent extension for home-state firm Procter & Gamble. He also signed a recent bipartisan letter requesting FDA action on the conjugated estrogens application of Cincinnati-based Duramed ("The Pink Sheet" Oct. 21, 1996, T&G-1). |